ELN LeukemiaNet
European

Assignment of groups and rooms
19th Congress of EHA, Milan, Thursday, June 12, 2014

TIME THURSDAY JUNE 12	Tourqouise 1	Tourqouise 2	SCIENTIFIC WORKING GROUPS
Coffee break 10:00 – 10:45			
10:45 – 12:45		SCT (WP14)	
Lunch break 12:45 – 13:30			
13:30 – 15:30	CML (WP4)	CLL/ERIC (WP7)	
Coffee break 15:30 – 16:15			
16:15 – 18:15	CMPD (WP9)	MDS (WP8)	
Official EHA Scientific Working Groups			
18:30 – 20:00			AML (WP5 + 12) ALL (WP6) CLL/ERIC (WP7)

ADDRESS: MiCo, Viale Eginardo (Gate 2), Milan, Italy

WP7 – CLL/ERIC - Meetings

Session 1. 35th General meeting of ERIC members
Chairpersons: E. Kimby and E. Montserrat

Date: *Thursday, June 12, 2014*
Time: *13:50 – 15:30*
Venue: *Room Tourqouise 2, MiCo congress center, Milan, Italy*

Agenda
- General information   *E. Montserra*
- New ERIC website
- Project Updates:
    - Recurrent gene mutations in CLL –   *R. Rosenquist*
      harmonization and future directions
    - The MRD Harmonisation Approach by   *P. Ghia/A. Rawstron*
      Flow Cytometry
- Other issues

Session 2. ERIC symposium / EHA scientific working group session

Cellular origin and immune system in CLL
Chairpersons: E. Kimby and E. Montserrat
Meeting Organizer: Federico Caligaris-Cappio (Milan, Italy)

Date: *Thursday, June 12, 2014*
Time: *18:30 – 20:00*
Venue: *Room Amber 1 + 2, MiCo congress center, Milan, Italy*

Programme
- Cell origin of CLL   *Ralf Kuppers*
                                                               (Essen, Germany)

- The innate immune system in CLL   *Martina Seiffert*
                                                               (Heidelberg, Germany)

- The clinical implications of understanding   *Carol Morena*
  immune deficiency and autoimmune   *(Barcelona, Spain)*
  phenomena in CLL
- Harnessing the immune sytem to treat (cure?) *Alan Ramsay*
  CLL   *(London, UK)*

![European LeukemiaNet logo]

WP8 - MDS - Meeting

Thursday, June 12, 2014
16:15 – 18:15

Room: Tourqouise 2
MiCo – Milano Congressi, Milan, Italy

Agenda

TOPIC: Consensus Meeting for guidelines for allogeneic SCT in MD

1. **Welcome and Recap**

2. **Summary of responses from expert panel**

3. **Topics to discuss**

    a. Controversial topics

    b. Missing topics

4. **Scenarios to discuss**

    a. Absence of consensus

    b. Missing scenarios

5. **General remarks or suggestions**

6. **Further planning**